| Biomarker ID | 1158 |
| PMID | 23826311 |
| Year | 2013 |
| Biomarker | 21PP + 5PP |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs Benign Prostatic Hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | 125 samples were divided into a discovery set with 22 PCa, 14 Chronic Prostatis; 9 BPH and 5 Healthy Control samples and the remaining 48 PCa, 12 BPH, 11 CP, and 4HC samples into an independent test set |
| Senstivity | Test Set: 83% (95% CI: 70%–93%) |
| Specificity | Test Set: 67% (95% CI: 46%–83%) |
| AUC | 0.75 (95% CI 0.64–0.83) |
| Accuracy | NA |
| Level Of Significance | p=0.0001 |
| Method Used | capillary electrophoresis mass spectrometry |
| Clinical | No |
| Remarks | 21PP: [Peptide ID: 3495; 3506; 3621; 3992; 4437; 4679; 4697; 5180; 6832; 7661; 8698; 9483; 9645; 10502; 11899; 12083; 13995; 14592; 15331; 18990; 19773]; 5PP: [Peptide ID: 7098; 8863; 9673; 10706; 24050]; Samples positive for 21PP (above the classification cut off) were re-classified using 5PP to specifically identify BPH excluding PCa. Therefore, samples positive for 21PP and negative for 5PP were considered as PCa, samples positive in either panels were considered as BPH and samples negative for 21PP (below the classification cut off) were considered as CP or HC control samples. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |